The iconic rise of Viagra has long been a benchmark of pharmaceutical success, yet its legacy within the broader sector now raises questions about potential returns . Alternative versions are eroding market share, prompting anxieties that supporting companies significantly dependent to Viagra's once-dominant standing could be a dangerous move , esp